<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Evaluation of solid form and thermodynamic properties for carbamazepine-saccharin (CBZ-SAC) co-crystal</title>
  </titleInfo>
  <name type="personal">
    <namePart>Fatinah Ab Rahman</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <typeOfResource manuscript="yes">text</typeOfResource>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">my</placeTerm>
    </place>
    <dateIssued encoding="marc">2020</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <extent>xiii, 92 pages : illustrations (some color) ; 30 cm. + 1 CD-ROM</extent>
  </physicalDescription>
  <abstract>The  formation  of  co-crystal  is  believed  to  improve  the  physicochemical  properties  of  Active Pharmaceutical Ingredients (API). Carbamazepine (CBZ) is a drug that is used as  anticonvulsant for treatment of epilepsy and known for having low solubility that can  affect the dosage intake in treating patients. It was used as model drug in this study with  saccharin (SAC) as co-crystal former. Co-crystallisation of CBZ and SAC was performed  to find the co-crystal solid form by varying solvents (ethanol, acetonitrile, ethyl acetate  and propanol), crystallisation methods (stirring crystallisation and slurry crystallisation)  and SAC/CBZ mol ratio (0.50, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75 and 3.00).  The solubility study and dissolution thermodynamic properties of the co-crystal at various  temperatures  (25-50  °C)  were  determined  in  pure  ethanol  solution  and  solution  with  excess of different SAC ratio. Differential Scanning Calorimetry (DSC), Powder X-Ray  Diffraction  (PXRD),  Fourier  Transform  Infrared  (FTIR)  and  optical  microscopy  were  used  to  characterise  the  co-crystal  solid  form,  while  High  Performance  Liquid  Chromatography (HPLC) and synthetic methods were used to determine the solubility of  the  co-crystal.  From  the  co-crystallisation  process,  CBZ-SAC  co-crystal  Form  I  was  successfully formed. SAC/CBZ ratio of 2.25 was chosen as the best ratio since it was the  highest ratio that has 100 % conversion of co-crystal. Stirring crystallisation method and  ethanol solvent were chosen as the best parameters among others due to CBZ-SAC cocrystal was able to form at higher ratio in this method and pure SAC more soluble in this  solvent.  Based  on  the  data  collected,  the  co-crystal  solubility  was  found  increases  as  temperature rises for all conditions used. HPLC was chosen as a better method compared  to the synthetic as HPLC reported the exact solubility value of the sample tested. The  solubility values of co-crystal were compared to be higher than pure CBZ solubility, thus  show  that  the  solubility  improved  with  the  formation  of  CBZ-SAC  co-crystal  at  temperatures of 25-50 °C. CBZ-SAC co-crystal ideal solubilities have positive deviation  and the experimental co-crystal solubility was correlated well with van’t Hoff model. The  thermodynamic  properties  (ΔsolH0,  ΔsolG0 and  ΔsolS0)  obtained  from  the  apparent  thermodynamic  analysis  have  positive  values  which  indicates  an  endothermic  and  entropy-driven dissolution of co-crystal in ethanol solvent. The data from this study could  amplify the physicochemical properties of CBZ-SAC co-crystal in aqueous solution and  the  pattern  of  the  CBZ-SAC  co-crystal  solubility  reacting  towards  temperatures  also  could be reported. The solubility and physicochemical data from this research could be  useful in purification, crystallisation, separation and formulation development of CBZ in  pharmaceutical and chemical industries.</abstract>
  <targetAudience authority="marctarget">specialized</targetAudience>
  <note type="statement of responsibility">Fatinah Ab Rahman</note>
  <note>Faculty of Chemical and Process Engineering Technology</note>
  <note>Thesis (Master of Science) -- Universiti Malaysia Pahang – 2020</note>
  <note>Includes bibliographical references</note>
  <subject authority="lcsh">
    <name type="corporate">
      <namePart>Faculty of Chemical and Process Engineering Technology</namePart>
    </name>
    <topic>Dissertations</topic>
  </subject>
  <subject authority="lcsh">
    <topic>Universities and colleges</topic>
    <topic>Dissertations</topic>
  </subject>
  <subject authority="lcsh">
    <topic/>
    <topic>Theses</topic>
  </subject>
  <identifier type="isbn">THE0009108(Local)</identifier>
  <recordInfo>
    <recordContentSource authority="marcorg">UMP</recordContentSource>
    <recordCreationDate encoding="marc">220217</recordCreationDate>
    <recordChangeDate encoding="iso8601">20251125110016.0</recordChangeDate>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
